STOCK TITAN

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.

In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.

Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.

With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.

Rhea-AI Summary

On August 19, 2021, Johnson & Johnson (NYSE: JNJ) announced that Alex Gorsky will transition into the role of Executive Chairman while Joaquin Duato, currently Vice Chairman, will become CEO, effective January 3, 2022. Gorsky has led the company as CEO since 2012, overseeing a 60% increase in R&D investments, reaching $12 billion in 2020. He emphasized the company's strong performance across all segments. Duato expressed enthusiasm for leading the company, highlighting its unmatched healthcare platform. The Board acknowledged the effective succession planning that enabled this leadership transition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary

On August 12, 2021, Johnson & Johnson (NYSE: JNJ) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 15, 2021. The company will be represented by Joseph J. Wolk, Executive Vice President and CFO, and Mathai Mammen, Global Head of Research & Development, during a session at 9:30 a.m. (Eastern Time). Investors can access the live webcast via the Johnson & Johnson website, with a replay available 48 hours post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Virtual Conference on September 10, 2021. The event will feature Thibaut Mongon, Executive Vice President Worldwide Chairman of Consumer Health, speaking at 9:20 a.m. (Eastern Time). Investors and other interested parties can access the webcast via the Johnson & Johnson website. A replay of the webcast will be available approximately 48 hours after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
conferences
Rhea-AI Summary

On July 29, 2021, lawmakers proposed reforms to prevent companies like Johnson & Johnson (JNJ) from using bankruptcy to evade liabilities related to talc products linked to ovarian cancer. The Nondebtor Release Prohibition Act aims to close loopholes such as non-consensual third-party releases and the Texas Two-Step strategy. JNJ has a market cap exceeding $400 billion and reported a 27% year-over-year sales increase to $23.31 billion, upgrading its annual forecast to $94.6 billion. Advocacy groups highlight the ethical implications of JNJ's potential bankruptcy strategy, stressing the need for corporate accountability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on September 10, 2021. Joaquin Duato, Vice Chairman of the Executive Committee, is set to represent the company in a session starting at 10:00 a.m. Eastern Time. Interested investors can access the live webcast via the Johnson & Johnson website. A replay of the webcast will be available approximately 48 hours after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences
-
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) reported impressive Q2 results with sales of $23.3 billion, up 27.1% year-over-year. Net earnings surged 73.1% to $6.3 billion, resulting in a diluted EPS of $2.35, a 72.8% increase. Key growth drivers included a 62.7% rise in Medical Devices sales, bolstered by market recovery from COVID-19, and a 17.2% increase in Pharmaceuticals, highlighted by strong performances from STELARA and DARZALEX. The Consumer Health segment also contributed with a 13.3% growth, driven by skin health products. JNJ emphasized ongoing innovations and external regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the third quarter of 2021. This dividend is set to be paid on September 7, 2021, to shareholders on record by August 24, 2021. The ex-dividend date is August 23, 2021. Johnson & Johnson continues its commitment to shareholder returns while focusing on improving health access and affordability globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
dividends
-
Rhea-AI Summary

Attorneys representing women diagnosed with ovarian cancer linked to Johnson & Johnson's (NYSE: JNJ) talc products are condemning potential bankruptcy plans aimed at limiting the company's liability. Reports suggest J&J, with a market cap of $443 billion, may exploit bankruptcy to mitigate financial responsibilities from ongoing lawsuits. Lawyers highlight a history of dangerous practices, including the company's failure to replace talc with safer alternatives. A previous $2.1 billion judgment against J&J reflects significant negligence. Critics argue bankruptcy filings would deny victims justice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary

On July 15, 2021, Beasley Allen law firm filed a federal class-action lawsuit against Johnson & Johnson (NYSE: JNJ) for selling benzene-tainted sunscreen products from its subsidiaries Neutrogena and Aveeno. The lawsuit seeks damages for consumers who purchased the affected items, which were recalled after lab tests revealed benzene levels exceeding safe limits. Benzene is a hazardous chemical linked to leukemia, raising serious health concerns, especially for children. The FDA prohibits benzene in sun-care products, yet J&J's recall only includes spray products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
Rhea-AI Summary

Johnson & Johnson Consumer Inc. (NYSE: JNJ) is recalling all lots of five aerosol sunscreen products due to low levels of benzene detected in some samples. This voluntary recall includes NEUTROGENA Beach Defense, Cool Dry Sport, Invisible Daily, Ultra Sheer, and AVEENO Protect + Refresh. Benzene, a human carcinogen, is not an ingredient but was found in finished products. While daily exposure at detected levels is not expected to cause harm, the recall emphasizes consumer safety. Consumers are instructed to stop using these products and contact the Consumer Care Center for refunds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $144.47 as of December 20, 2024.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 347.0B.

What are the main business segments of Johnson & Johnson?

Johnson & Johnson operates through three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products.

What recent developments have there been in Johnson & Johnson's pharmaceutical division?

Recently, Johnson & Johnson received expanded FDA approval for CARVYKTI®, a therapy for multiple myeloma, based on positive Phase 3 study results.

What products are included in Johnson & Johnson’s consumer health segment?

The consumer health segment includes products in baby care, beauty, oral care, over-the-counter drugs, and women's health.

What is CARVYKTI®?

CARVYKTI® is a one-time infusion therapy for multiple myeloma, recently approved for expanded use due to its efficacy in delaying disease progression.

What percentage of Johnson & Johnson's revenue is generated in the United States?

Over half of Johnson & Johnson’s total revenue is generated in the United States.

What is the focus of Johnson & Johnson’s medical devices segment?

The medical devices segment focuses on orthopedics, surgical instruments, and vision care.

What changes are happening with Johnson & Johnson’s consumer health division?

The consumer health division is being divested in 2023 and will operate under the new name Kenvue.

How does Johnson & Johnson contribute to global healthcare?

Johnson & Johnson develops innovative solutions to prevent, treat, and cure complex diseases, aiming to improve global health.

Where can I find more information about Johnson & Johnson?

More information about Johnson & Johnson can be found on their official website at www.jnj.com.

What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?

The pharmaceutical division focuses on immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases.

Johnson & Johnson

NYSE:JNJ

JNJ Rankings

JNJ Stock Data

347.01B
2.41B
0.09%
73.15%
0.73%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW BRUNSWICK